Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

NCT01487096 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01487096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01487096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2001
Completion date
March 31, 2003
Enrollment
179 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis